Cullinan Therapeutics: CLN-619 Mechanism of Action
One of the hallmarks of cancer is the ability to avoid detection by the immune system. Cancer cells get selected for escape mechanisms that can render them invisible to immune cells. The resulting immune evasion enables tumor growth and metastasis. There is a significant unmet need for novel therapies that can help overcome immune evasion mechanisms employed by tumors. CLN-619 is a potential first-in-class humanized lgG1 monoclonal antibody that binds to the stress induced ligands MICA and MICB, which are expressed on a wide variety of solid tumors and hematologic malignancies. CLN-619 restores the MICA/B-NKG2D axis to promote NK-mediated tumor cell lysis. Learn more about CLN-619 at https://cullinantherapeutics.com/programs/.